Search Page

1

Cite

Share

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial.

Kaufmann H, Vickery R, Wang W, Kanodia J, Shibao CA, Norcliffe-Kaufmann L, Haumann B, Biaggioni I. Kaufmann H, et al. Among authors: haumann b. Clin Auton Res. 2021 Dec;31(6):699-711. doi: 10.1007/s10286-021-00827-0. Epub 2021 Oct 17. Clin Auton Res. 2021. PMID: 34657222 Free PMC article. Clinical Trial.

Cite

Share

2

Cite

Share

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.

Singh D, Bogus M, Moskalenko V, Lord R, Moran EJ, Crater GD, Bourdet DL, Pfeifer ND, Woo J, Kaufman E, Lombardi DA, Weng EY, Nguyen T, Woodcock A, Haumann B, Saggar R. Singh D, et al. Among authors: haumann b. Eur Respir J. 2021 Oct 14;58(4):2100673. doi: 10.1183/13993003.00673-2021. Print 2021 Oct. Eur Respir J. 2021. PMID: 34210790 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease.

Donohue J, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Donohue J, et al. Among authors: haumann b. Data Brief. 2019 Aug 22;26:104277. doi: 10.1016/j.dib.2019.104277. eCollection 2019 Oct. Data Brief. 2019. PMID: 31534988 Free PMC article.

Cite

Share

4

Cite

Share

The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol.

Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. Vestbo J, et al. Among authors: haumann b. Eur Respir J. 2013 May;41(5):1017-22. doi: 10.1183/09031936.00087312. Epub 2012 Sep 27. Eur Respir J. 2013. PMID: 23018908 Free article. Clinical Trial.

Cite

Share

5

Cite

Share

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.

Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Donohue JF, et al. Among authors: haumann b. Respir Med. 2019 Jul;153:38-43. doi: 10.1016/j.rmed.2019.05.010. Epub 2019 May 23. Respir Med. 2019. PMID: 31150963 Free article. Clinical Trial.

Cite

Share

6

Cite

Share

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.

Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD. Donohue JF, et al. Among authors: haumann b. BMC Pulm Med. 2020 May 11;20(1):134. doi: 10.1186/s12890-020-1156-4. BMC Pulm Med. 2020. PMID: 32393215 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).

Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Donohue JF, et al. Among authors: haumann b. Respir Res. 2019 Oct 30;20(1):241. doi: 10.1186/s12931-019-1187-7. Respir Res. 2019. PMID: 31666076 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.

Ferguson GT, Feldman G, Pudi KK, Barnes CN, Moran EJ, Haumann B, Pendyala S, Crater G. Ferguson GT, et al. Among authors: haumann b. Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):154-165. doi: 10.15326/jcopdf.6.2.2018.0152. Epub 2019 Apr 9. Chronic Obstr Pulm Dis. 2019. PMID: 30974049 Free PMC article.

Cite

Share

9

Cite

Share

Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.

Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW. Bateman ED, et al. Among authors: haumann b. Respir Med. 2012 May;106(5):642-50. doi: 10.1016/j.rmed.2012.01.004. Epub 2012 Feb 18. Respir Med. 2012. PMID: 22342538 Free article. Clinical Trial.

Cite

Share

10

Cite

Share

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma.

Woodcock A, Bleecker ER, Busse WW, Lötvall J, Snowise NG, Frith L, Jacques L, Haumann B, Bateman ED. Woodcock A, et al. Among authors: haumann b. Respir Res. 2011 Dec 21;12(1):160. doi: 10.1186/1465-9921-12-160. Respir Res. 2011. PMID: 22188590 Free PMC article. Clinical Trial.

Cite

Share